MGC Pharmaceuticals (ASX:MXC) progresses brain cancer research
ASX:MXC MCAP $36.09M
· Bio-pharma company MGC Pharmaceuticals (MXC) has progressed its research program using cannabis to develop a treatment for glioblastoma, an aggressive type of brain tumour
· The company tested 18 patient tumour samples using a cannabidiol (CBD) and cannabigerol (CBG) formula
· It found that CBD slowed the viability of the cancer, while CBG increased the death rate of cancerous cells
· Following the successful program, MGC will continue the research, aiming for a human clinical trial next year
· On the market this morning, MGC is in the grey and trading for 2.2 cents per share
MGC Pharmaceuticals (MXC) has further progressed its ongoing research program to develop a treatment for an aggressive brain tumour known as glioblastoma.
The company is currently testing cannabinoid formations on the therapeutically resistant tumour. The research is focused on the use of cannabidiol (CBD) and cannabigerol (CBG) after successful program results in April.
Read the full article on The Market Herald here: https://themarketherald.com.au/mgc-pharmaceuticals-asxmxc-progresses-brain-cancer-research-2020-11-17/
MGC Pharmaceuticals (ASX:MXC) progresses brain cancer...
Add RGT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
41.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $18.56M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1300 | 41.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 43.0¢ | 3173 | 2 |
View Market Depth
| Last trade - 07.33am 19/04/2024 (20 minute delay) ? |
| RGT (ASX) Chart |
Day chart unavailable